Dr Philip Gould

Phil Gould joined the Board of Lectus Therapeutics in early 2003 as Non-Executive Chairman and had chaired it from its first Board meeting.

Phil Gould was educated at Hull University with a Special Honours Degree in Chemistry (1975) and then a PhD in Chemical kinetics (1978). He is a Chartered Chemist, an Honorary Professor of Health Sciences and a Member of the Institute of Directors. Phil has also been an expert witness in patent litigation, and a business advisor to a UK university.

Phil joined Reckitt and Colman Pharmaceuticals Division in 1978 working in the area of drug design. From 1980 to 1985, he held a range of scientific roles with Pfizer Central Research and worked with the teams that discovered and developed fluconazole. In 1988 he joined Lederle Laboratories (now part of Wyeth) as Senior Manager in Pharmaceutical Development working closely with the Commercial and product supply groups. In 1993 he joined Glaxo, progressing through functional, divisional and site roles, which increased in seniority. In 1995 he was appointed to the post of Head of New Product Introduction, responsible for Glaxo's UK New Product Supply Technology across its 4 manufacturing sites working closely with R&D and Commercial groups across the world. In 1998 Phil went on to become Chief Executive Officer of Provalis PLC, a pharmaceuticals and diagnostics group, leading it to its first profit in 2003 and to enter European markets for its pharmaceutical products and the USA market for its diagnostics products.

In early 2006 Phil set up and is presently the Managing Director of Jadara Pharma, a Healthcare Business Consultancy focusing on business strategic planning and new product introduction.